Protein in the diet is vital for liver function: Study
April 7, 2017
Hepatitis C drug faces fresh battle
April 10, 2017
Show all

Biogen wins patent ruling for its $4 billion multiple sclerosis treatment

Patent challenge on multiple sclerosis medication.

Shares of Biogen Inc. were trading up 1.5 percent early Tuesday afternoon after the Cambridge biotech’s patent on its top-selling multiple sclerosis treatment was upheld by a legal ruling.

The U.S. Patent Trial and Appeal Board rejected a patent challenge by Texas hedge fund manager Kyle Bass, who has been working for years to invalidate key intellectual property rights of Biogen and other biotechnology companies. A ruling in favor of the Bass-led Coalition for Affordable Drugs could have hurt Biogen’s revenue from the oral MS drug Tecfidera, which generated nearly $4 billion in sales last year.

Biogen settled part of a separate ongoing patent dispute with Denmark’s Forward Pharma A/S in January, agreeing to pay $1.2 billion to license Forward Pharma’s intellectual property covering an active ingredient in Tecfidera. Investors are awaiting a pending decision in a separate part of that case, in which Forward Pharma is seeking annual royalties from Biogen on the sale of Tecfidera.

Read full article: Biogen wins patent ruling for its $4 billion multiple sclerosis treatment – The Boston Globe

Read Full Article: Biogen wins patent ruling for its $4 billion multiple sclerosis treatment – The Boston Globe 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.